PMID- 32939795
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 46
IP  - 2
DP  - 2021 Mar
TI  - De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of 
      programmed death-1 or programmed death ligand-1 inhibitor therapy: 
      clinicopathological correlation.
PG  - 328-337
LID - 10.1111/ced.14449 [doi]
AB  - Immune checkpoint inhibitors (ICI) may cause eruptions resembling cutaneous 
      autoimmune diseases. There are six cases of immunotherapy-associated subacute 
      cutaneous lupus erythematosus (SCLE) in the literature. We present details of 
      five patients referred to the Skin Toxicity Program at the Dana-Farber Cancer 
      Institute/Brigham and Women's Cancer Center who developed de novo 
      immunotherapy-associated SCLE-like eruptions, along with clinicopathological 
      correlation and highlight potential mechanistic features and important diagnostic 
      points. Two patients were maintained on topical corticosteroids, antihistamines 
      and photoprotection. One had complete clearance and two had improvement with 
      addition of hydroxychloroquine. Four patients continued their immunotherapy 
      uninterrupted, while one had immunotherapy suspended for a month before 
      restarting at full dose. Histopathologically, this series illustrates the 
      temporal evolution of ICI-induced immune cutaneous reactions with SCLE subtype. 
      Looking beyond the universally present lichenoid infiltrate, features of evolving 
      SCLE were evident. We hypothesize that programmed death-1 blockade may induce 
      immunological recognition of previously immunologically tolerated drug antigens, 
      leading to epitope spreading and the SCLE phenotype.
CI  - (c) 2020 British Association of Dermatologists.
FAU - Bui, A N
AU  - Bui AN
AUID- ORCID: 0000-0003-0133-7935
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Hirner, J
AU  - Hirner J
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Singer, S B
AU  - Singer SB
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Eberly-Puleo, A
AU  - Eberly-Puleo A
AD  - Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and 
      Women's Cancer Center, Boston, MA, USA.
FAU - Larocca, C
AU  - Larocca C
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Lian, C G
AU  - Lian CG
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
FAU - LeBoeuf, N R
AU  - LeBoeuf NR
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
AD  - Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and 
      Women's Cancer Center, Boston, MA, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201014
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antimalarials)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Administration, Topical
MH  - Adrenal Cortex Hormones/administration & dosage/therapeutic use
MH  - Aged
MH  - Antimalarials/administration & dosage/therapeutic use
MH  - Combined Modality Therapy
MH  - Exanthema/*pathology
MH  - Female
MH  - Histamine Antagonists/administration & dosage/therapeutic use
MH  - Humans
MH  - Hydroxychloroquine/administration & dosage/therapeutic use
MH  - Immune Checkpoint Inhibitors/*adverse effects/therapeutic use
MH  - Immunotherapy/adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/*drug therapy
MH  - Retrospective Studies
MH  - Sun Protection Factor
MH  - Treatment Outcome
MH  - Withholding Treatment
EDAT- 2020/09/18 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/09/17 05:48
PHST- 2020/03/11 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/09/17 05:48 [entrez]
AID - 10.1111/ced.14449 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2021 Mar;46(2):328-337. doi: 10.1111/ced.14449. Epub 2020 Oct 
      14.